Product description

Product name:Cipro

Company name:

DIN:00596785

Status:Common

Status date:2025-01-02

Active ingredient(s)	Strength
CIPRO(CIPROFLOXACIN)	5 MG

Resources

Click on a resource to visit a page with more information. You may be taken away from this page to a different Government of Canada website.

For consumers

Resource	Description
The Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use. The Product Monograph includes three sections: Part I: Health Professional Information; Part II: Scientific Information; and Patient Medication Information
Side effects are troublesome symptoms or feelings that you may not expect that show up when you are taking a medicine. All suspected side effects should be reported, especially those that are: Unexpected, regardless of their severity, i.e., not consistent with product information or labelling; or Serious, whether expected or not, i.e., that requires being admitted to the hospital, lengthened hospital stay, causes a birth defect, disability, is life-threatening or results in death; Reactions to recently marketed health products (on the market for less than five years), regardless of their nature or severity.

For health care professionals

Section C.01.020.1 of the Food and Drug Regulations and section 62 of the Medical Devices Regulations, require hospitals to report to Health Canada all serious adverse drug reactions (ADRs) and medical device incidents (MDIs) within 30 days of being documented within the hospital. This regulatory requirement only applies to hospitals.

For researchers

After Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes.

All resources

Description

Ciprofloxacin 500mg/5ml is an antibiotic medicine that belongs to the fluoroquinolone family. It is used to treat various bacterial infections such as ear, nose, and throat infections, urinary tract infections, skin and soft tissue infections, and skin and soft tissue infections. Ciprofloxacin 500mg/5ml may also be used for the treatment of infections caused by susceptible strains of bacteria. It is also used to treat certain infections in the body caused by organisms that are resistant to this antibiotic.

Precautions

Uses of Ciprofloxacin 500mg/5ml

• Treats susceptible strains of bacteria, such as Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Enterobacter species, Proteus mirabilis, Streptococcus faecalis, and other bacteria.
• Used for the treatment of infections caused by susceptible strains of bacteria.
• May cause nausea, vomiting, diarrhea, and vomiting (feeling or being sick).
• Not recommended for children under eight years of age due to the risk of ear infections.
• May be used for the treatment of certain types of bacterial infections.
• Not recommended for pregnant or breastfeeding women due to the risk of ear infections.

How to use Ciprofloxacin 500mg/5ml

• Take the medicine as advised by your doctor.
• Swallow the tablets whole with a glass of water.
• Do not crush, chew, or break the tablets.
• Take the medicine at the same time each day.
• The duration of treatment should be decided by your doctor based on your symptoms and health conditions.
• Do not take this medicine more than 1 time per day.
• Do not take Ciprofloxacin 500mg/5ml more than once a day.

Missed Dose

• If you miss a dose of Ciprofloxacin 500mg/5ml, take it as soon as possible. However, if it is close to the time for your next dose, skip the missed dose and go back to your regular dosing schedule.
• Do not double the dose to catch up.

Storage Instructions

• Store Ciprofloxacin 500mg/5ml at room temperature.
• Do not keep it in the bathroom or in the car until it is time to use it.
• Keep the medicine out of the reach of children.

Side Effects

Common side effects of Ciprofloxacin include nausea, vomiting, diarrhea, and cramps. Less common side effects may include temporary or permanent joint deformities (such as osteoarthritis or aplastic ankylosing spondylitis). Less common side effects may occur in rare cases and may include liver dysfunction, rash, photosensitivity, and photosensitivity/allergy symptoms.

Serious side effects of Ciprofloxacin include sudden hearing loss, ringing in the ears, prolonged QT interval, and anaphylaxis. These serious side effects require immediate medical attention and treatment as described in the package leaflet or by the doctor or pharmacist.

Do not use in pregnancy or breastfeeding as the risk of harm to the fetus comes into play. Ciprofloxacin can harm an unborn baby. Use with caution in patients with a history of heart problems, diabetes, high blood pressure, high cholesterol, or any other known heart disease or diabetes. Pregnancy is a possible risk. Ciprofloxacin is not recommended for use during breastfeeding.

POPULATION

Ciprofloxacin 500mg/5ml is for use in adults and children aged 6 years and older only. Do not use in children more than 6 years of age or in those with a known history of allergic reactions (e.g., a skin rash, itching, or difficulty breathing). Always read the package leaflet before using Ciprofloxacin 500mg/5ml for children. Do not use in those with a known history of hypersensitivity (e.g.

1. Introduction

The aim of the antibiotic ciprofloxacin (CIP) is to improve its efficacy against gram-positive and gram-negative pathogens. It is a broad-spectrum antibiotic of tetracycline class, which is effective in treating a wide range of bacterial infections. CIP is widely used in the medical field because of its broad-spectrum activity, making it a preferred choice in many countries [

].

The mechanism of action of ciprofloxacin involves two distinct pathways: a reduction in bacterial cell wall permeability and an increase in bacterial protein synthesis [

This alteration results in the inhibition of bacterial protein synthesis, which promotes the growth of resistant bacteria, and subsequently, in the inhibition of bacterial cell wall permeability [

The inhibition of bacterial protein synthesis by ciprofloxacin results in an increase in bacterial cell wall permeability and an increase in bacterial protein synthesis [

The inhibition of bacterial cell wall permeability results in an increased bacterial cell wall synthesis and a decrease in bacterial protein synthesis [

These effects are mediated by the inhibition of bacterial protein synthesis in a cell wall. The inhibition of bacterial cell wall synthesis can result in the loss of bacterial cell wall synthesis, which in turn results in the loss of cell wall permeability [

The mechanism of action of ciprofloxacin includes the inhibition of bacterial protein synthesis and the inhibition of cell wall synthesis. In addition to inhibition of bacterial cell wall synthesis, the inhibition of bacterial protein synthesis can also result in the development of drug resistance, which is a global health issue. The development of new drugs for the treatment of infections is a significant challenge for public health and is a global health issue.

Therefore, it is important to know that the mechanisms of action of ciprofloxacin and the mechanism of action of bacterial protein synthesis inhibition are the same [

This makes it important to develop new drugs and develop treatments against Gram negative and Gram positive bacteria, as well as for other bacterial pathogens [

This review will discuss the pharmacological aspects of ciprofloxacin and bacterial protein synthesis inhibition. It will also discuss the importance of the antibiotic ciprofloxacin in the treatment of bacterial infections. The focus will be on the mechanism of action, clinical outcomes, and the importance of this drug in the treatment of bacterial infections. It is expected that the pharmacological effects of ciprofloxacin will be reflected in the development of new treatments for bacterial infections.

2. Pharmacokinetic Parameters of ciprofloxacin and bacterial protein synthesis inhibition

2.1. Effect of ciprofloxacin on the pharmacokinetics of ciprofloxacin and bacterial protein synthesis inhibition

The pharmacokinetics of ciprofloxacin and the bacterial protein synthesis inhibition have been studied in many studies. The pharmacokinetics of ciprofloxacin are described in detail in

The results show that ciprofloxacin (5 mg/kg) has a high bioavailability, with a maximum plasma concentration of around 300 ng/mL, with a mean terminal elimination half-life of 2.3 hours, in comparison to the standard recommended daily dose (

). The pharmacokinetic parameters of the antibiotic ciprofloxacin (5 mg/kg) have been determined using a bioequivalent dose (

The pharmacokinetic parameters of ciprofloxacin (5 mg/kg) have been determined using a bioequivalent dose (

2.2.

The pharmacokinetics of ciprofloxacin (5 mg/kg) have been studied in several studies. The results show that ciprofloxacin (5 mg/kg) has a high bioavailability, with a mean terminal elimination half-life of around 2 hours, in comparison to the standard recommended daily dose (

Description

The primary aim of this study is to evaluate the effect of tetracyclines on Ciprofloxacin HCl pka value in the presence of aqueous medium. In addition, the effect of tetracycline and clindamycin on the Ciprofloxacin HCl pka value in the presence of aqueous medium was investigated.

Materials and Methods

In Vitro Solution and Tetracycline Hydrochloride (25 mg, 1.0 molar) Tablet

The ciprofloxacin hydrochloride was obtained from the commercial drug company, Pfizer. Ciprofloxacin HCl was purchased from Zydus Pharmaceutica, Inc. (Poklodin, Croatia). Clindamycin HCl was obtained from Pfizer (Olym, Croatia). The drug preparation for human and dog kidney tubular secretion was purchased from Sigma-Aldrich (St. Louis, USA). The tetracyclines were prepared according to a published procedure.

In Vitro Infusion (200 ml, 20°C) and DMSO (10 mg/ml) Solutions

Ciprofloxacin hydrochloride was dissolved in a solution of 0.5 mol/L of dibenzo-carnitine (0.5, 1, 2, 3.2, 3.8, 5, 7.8, and 8.2 mg), and then diluted in an equivalent volume of 0.5 mol/L of deionized water, and then added to the solutions containing the other compounds.

Optical Microscopy: A 100-W UV-Vis Spectrophotometer

The optical microscope (Olympus, Eige,viron) was used to observe the morphology and the number of pores in the ciprofloxacin hydrochloride solution.

Hydrochloric Acid

Ciprofloxacin hydrochloride was dissolved in a solution of 20 mg/ml and then diluted to a final concentration of 0.05% and 0.1% in a solution of 5 mL. The volume was adjusted to 20 ml and the pH was adjusted to 4.0.

Glycerol Free Fraction

The solubility of ciprofloxacin hydrochloride in methanol and water was determined by the method ofautions and excipients, and the optimal conditions for this method were selected.

Pelvic Inflammatory and Diabetic Clinical Trials (PICD) Study Group

PICD Study Group consisted of 2,000 men and 2,000 women who had undergone a median of 7 menstrual cycles, and were given 400 mg of ciprofloxacin hydrochloride in the last 6 months. All participants were randomly assigned to one of the four treatment groups by a computerized randomization table. In the first group, the primary end points were clinical severity of pain and quality of life (including the number of days spent in pain/mildness and pain-related functional impairment), and in the second group, the clinical end points were adverse event data during the first 3 months of treatment. In the third group, the primary end points were adverse event data during the third month of treatment. The clinical end points were adverse event data during the first 3 months of treatment.

Drug Administration:

The drug formulations were prepared according to the literature and the drug concentrations were prepared as follows: Ciprofloxacin hydrochloride (25 mg), ciprofloxacin (1.0 molar) and dibenzo-carnitine (2.0 molar), in 0.5 mol/L of solution.

Preparation of Ciprofloxacin Hydrochloride

In the presence of 0.5 mol/L of dibenzo-carnitine (0.5, 1, 2, 3.2, 3.8, 5, 7.8, and 8.2 mg), 10 mg/ml of ciprofloxacin hydrochloride solution was dissolved in 0.5 mol/L of deionized water (0.5, 1, 2, 3.2, 3.8, 5, 7.8, and 8.2 mg). The pH of the solution was adjusted to 4.0.

Sold and Supplied by Healthylife Pharmacy

Ciproxin Ciproxin (500mg) 30 Tablets

This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.

Medicare CardNo MedicareConcession

$28.95

Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.